COMPASS THERAPEUTICS INC. - COMMON STOCK

Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21

15 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

01 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

22 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

09 Nov 2022 08:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Present at Upcoming Investment Conferences

08 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Compass Therapeutics Announces $80 Million Private Placement

02 Nov 2022 08:06:54 By Nasdaq GlobeNewswire

Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab)

11 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

09 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference

02 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Compass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

31 May 2022 07:00:01 By Nasdaq GlobeNewswire

Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference

23 May 2022 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

09 May 2022 07:00:02 By Nasdaq GlobeNewswire

Compass Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 11:20 a.m. PT

05 May 2022 07:00:02 By Nasdaq GlobeNewswire

Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers

04 May 2022 06:00:01 By Nasdaq GlobeNewswire

Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

03 May 2022 15:01:00 By Nasdaq GlobeNewswire

Compass Therapeutics Announces Appointment of Two New Directors to its Board

26 Apr 2022 07:00:03 By Nasdaq GlobeNewswire

Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting

08 Apr 2022 12:01:00 By Nasdaq GlobeNewswire

Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans

30 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

21 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

20 Jan 2022 07:30:00 By Nasdaq GlobeNewswire